D-Medical Industries
is a publicly traded company on the Tel Aviv Stock Exchange (DMED) and on the NASDAQ (DMED). The company, through its subsidiary
Spring Health Solutions Ltd (formerly NiliMEDIX), is engaged in the full product life cycle of research, development, manufacturing, and sales of cost-effective drug delivery devices.
The company We are a medical device company engaged through our subsidiaries in the research, development, manufacture and sale of innovative products for diabetes treatment and drug delivery. We have developed durable and semi-disposable insulin pumps, which continuously infuse insulin into a patient’s body using our proprietary spring-based delivery technology. We believe that our spring-based delivery mechanism is cost-effective compared to a motor and gear train and allows us to incorporate certain advantageous functions and design features in our insulin pumps.
Location Our registered office is located at 3 HaSadna St., Tirat Carmel 39032, Israel. Our telephone number is +972-73-2507100. Our website address is www.dmedicalindustries.com and we have recently launched a new website, www.springnow.com, which is primarily intended for physicians and diabetes patients.
Business Background We commenced sales and marketing operations in late 2009 and are currently selling our Spring Zone Insulin Delivery System, or Spring Zone Pump, to our distributors mainly in Europe. We have also engaged distributors in Poland, Sweden, the Netherlands and Belgium, the Czech Republic, Italy, Greece, Mexico and China to sell and market our products in those countries, and, subject to our receipt of the necessary regulatory approvals, we intend to begin selling our products in these markets in the future. Our Spring Universal Infusion Sets include unique features, such as our proprietary detach-detect mechanism, which alerts a patient when the infusion set detaches from the patient’s body. We are also in the process of developing our Spring Hybrid Patch Pump, a semi-disposable insulin patch pump, and have commenced its commercialization process by transitioning it from a research and development product to a product that we can sell in large quantities.
While we intend to roll out our products initially in Europe, we also plan to focus on our commercialization efforts in the BRIC countries and Mexico. We have already entered into distribution agreements with respect to Mexico and China, although we have not yet obtained the required regulatory approvals and do not presently sell our products in the BRIC countries and Mexico.
Our research and development operations are ongoing and are focused on creating the next generation of our insulin pumps, including a simplified semi-disposable insulin pump specifically designed to treat Type 2 diabetes patients who typically do not begin using insulin until later in life and, therefore, are generally less amenable to complex insulin delivery user interface. We are also focused on developing a device that will combine a continuous glucose monitoring system and an insulin pump on the same patch.
We operate mainly through our subsidiary, Spring Health Solutions, which has developed our core proprietary technology, the spring-based delivery mechanism, and is now focused on manufacturing and marketing our Spring Zone Pump, as well as the final stages of development of our Spring Hybrid Patch Pump. Spring Health Solutions also operates in conjunction with Spring-Set Health Solutions on manufacturing and marketing our Spring Universal
Infusion Sets. G-Sense focuses on researching and developing a continuous glucose monitoring system and intends to cooperate with Spring Health Solutions to develop a combined continuous glucose monitoring and insulin pump device on one patch.